Samchundang Pharmaceutical Refutes Controversy Over Taiwanese Filing, Asserts Exclusive Ownership of S-PASS Patent
"Under Commissioned Research Structure, Rights Belong to the Funder"
Summit Listed as Applicant Is Administrative Process... Actual Rights and Profits Held by Samchundang
Samchundang Pharmaceutical has refuted reports that the patent for its drug delivery platform "S-PASS" was filed under the name of Taiwanese company Summit Biotech, asserting that all rights to the technology belong exclusively to itself.
Jeon Inseok, CEO of Samchundang Pharm, is speaking at a press conference held on the 6th at the Samchundang Pharm headquarters in Seocho-gu, Seoul. Photo by Yonhap News
View original imageOn April 7, Samchundang Pharmaceutical released a statement explaining, "In 2018, we signed a contract with Summit Biotech in Taiwan for the development of the S-PASS technology," and added, "Under the arrangement, Samchundang Pharmaceutical covered the entire cost of research and development, including animal testing expenses and researcher salaries. In return, all legal rights, such as patent ownership and commercialization rights, are vested in Samchundang Pharmaceutical."
Previously, some media outlets reported that Summit Biotech had filed a patent related to S-PASS in June 2024, noting it is unusual for a foreign company with no equity relationship to hold a core patent. There was also speculation that, if the technology had been transferred to an unlisted company, it could raise concerns of breach of duty.
In response, the company stated, "In the pharmaceutical and biotech industries, it is standard practice for the results of 'commissioned research'—where the funding party supports the project and the research institution performs the development—to belong to the funder. The fact that Summit is listed as the applicant on the international patent is merely an administrative procedure to indicate the research performer. The actual rights and profits are held by Samchundang Pharmaceutical."
Samchundang Pharmaceutical also asserted, "The S-PASS technology disclosed in this international patent (WO 2025/255759 A1) is considered to surpass the limitations of SNAC, which is a global standard technology." The company further explained, "S-PASS employs a dual absorption mechanism combining micelle complexes and biological complexes, enabling an injection-level rapid effect while protecting peptides from gastric acid and digestive enzymes. It is designed as a solid formulation that does not use oil, improving distribution stability and convenience of administration." The company added, "Securing this patent is expected to allow us to maintain exclusive rights to the platform technology until around 2045."
A Samchundang Pharmaceutical representative stated, "As seen in the disclosed contract, since this project involved significant funding, all legal rights belong to Samchundang Pharmaceutical. Ongoing projects are also structured so that our company bears the research expenses." Addressing claims that Summit Biotech’s entity is unclear, the spokesperson countered, "If the company did not exist, it would have been impossible for the patent application to be filed in the first place."
Regarding the controversy at the previous day's press conference, where Dios Pharma CEO Suk Sangje spoke without revealing his identity, the company explained, "Since 2014, CEO Suk has served as an overseas business development advisor for the Global Business Division and is highly specialized in this field. There was some lack of experience in handling the first press conference."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
During the briefing, CEO Suk provided additional explanations regarding whether the U.S. Food and Drug Administration (FDA) would recognize oral semaglutide as a generic, but reportedly left the venue without answering questions about his identity, which led to further skepticism.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.